Recommendations of the SEC (Ophthalmology) made in its 50th meeting held on 29.10.2021at CDSCO HQ New Delhi:

S.No	File Name & Drug Name, Strength	Firm Name	Recommendations
FDCDivision			
1.	FDC/IMP/21/000009 Carbomer 980-0.2%w/v + Sodium Hyaluronate EP 0.2% w/v eye drops	M/s. Medicom	In light of the earlier recommendations of the SEC dated 25.6.2021, the firm presented their proposal before the Committee. After detailed deliberation, the committee recommended that firm should conduct a Phase III clinical trial on the Indian patients to generate the efficacy and safety data. Accordingly firm should submit Phase III trial protocol for further review by the committee.
Medical Device Division			
2.	4-MD/CT-192/2017 EndoArt	Hyderabad Eye Research Foundation	The firm did not turn up for the presentation.
3.	CI/MD/2021/46557 Trifocal Hydrophobic Aspheric Intraocular Lens	M/s. Bio-Tech Vision Care Pvt. Ltd.	The firm presented their proposal before the committee. After detailed deliberation, the committee recommended for grant of permission to conduct post marketing clinical investigation in the country.